SecBot SecBot
PRESS-RELEASE ·Filed Jul 27, 2026

CGON

CG Oncology Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The Lancet publication provides independent peer-reviewed validation of the BOND-003 data, which may increase the probability of FDA approval for cretostimogene in BCG-unresponsive NMIBC. Traders should monitor for the FDA decision date and any pre-submission meeting outcomes; a positive approval would be transformative for this single-asset company with a $6.1B market cap.

DirectionBullish
Confidencehigh
Horizonweeks

cretostimogene

▲ Bullish Named in this press release
Impact
Phase
Phase 3
Time to market
BLA submission planned for Q4 2026 in BCG-unresponsive NMIBC. If accepted and approved under standard FDA review, potential approval could come in H2 2027. The drug already has Breakthrough Therapy designation from the FDA.
Next catalyst
None dated

What to watchWatch for BLA submission completion in Q4 2026, this is the key catalyst that will determine whether cretostimogene becomes the first FDA-approved oncolytic virus therapy for NMIBC. Also monitor PIVOT-006 Phase 3 topline data (intermediate-risk NMIBC), which could be imminent. The $1.05B ATM facility creates ongoing dilution overhang, so positive regulatory catalysts are needed to offset that pressure.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$72.62
T+0 close · Jul 27, 2026 · via day close
Latest settled
−14.29%
T+60 · $62.24
Vs SPY
−18.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 28 $72.62entry
  2. T+1 · 4mo ago −4.82%α −3.28% · $69.12
  3. T+5 · 4mo ago −4.78%α −7.05% · $69.15
  4. T+20 · 3mo ago +8.72%α +5.34% · $78.95
  5. T+60 · 27d ago −14.29%α −18.64% · $62.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CG Oncology published Phase 3 BOND-003 Cohort C results for cretostimogene in BCG-unresponsive NMIBC in The Lancet Oncology, showing a 75.5% complete response rate, median duration of response of 27.9 months, and no Grade 3+ treatment-related adverse events. The publication validates the clinical data ahead of a potential FDA decision, reinforcing the drug's profile as a potential bladder-sparing therapy in a high-need setting with no approved standard of care alternatives beyond cystectomy.

Key Facts

  • Phase 3 BOND-003 Cohort C met its primary endpoint with statistical significance; 75.5% of patients achieved complete response at any time.
  • Median duration of response was at least 27.9 months and is ongoing; 64.2% and 60.1% maintained response at 12 and 24 months, respectively.
  • No Grade 3 or greater treatment-related adverse events, treatment-related discontinuations, or deaths reported.
  • 96.6% of patients were free from progression to muscle-invasive bladder cancer at 48 and 96 weeks.
  • Cretostimogene has FDA Fast Track and Breakthrough Therapy designations; BOND-003 enrolled 112 patients globally.

Financial Impact

No financial figures provided in the press release; CG Oncology is a late-stage clinical biopharmaceutical company with no approved products or disclosed revenue.

pipeline valueregulatory probability of success

Risk Factors

  • FDA may still issue a Complete Response Letter (CRL) on safety/efficacy or CMC grounds, which would be severely negative for a single-asset biotech.
  • Competing bladder-sparing therapies (e.g., intravesical gemcitabine-docetaxel, pembrolizumab) may limit commercial uptake even if approved.
  • Forward-looking statements caution that interim results are not necessarily indicative of final outcomes; regulatory review timelines are uncertain.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3333936

Track record

25 reports on CGON

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 27, 2026